文献速递类风湿关节炎

已确诊类风湿关节炎向无DMARD缓解的减量策略:TARA试验2年结果

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial.
PubMed 文献 · Ann Rheum Dis · 2020-06-01

TARA试验纳入189例病情控制稳定的已确诊RA患者,随机比较先减csDMARD后减TNF抑制剂与相反顺序的两种策略。24个月累积复发率分别为61%和62%,组间DAS、HAQ-DI及影像学进展无差异;先减csDMARD组达到无DMARD缓解的比例数值上更高(21% vs 10%,p=0.07)。

要点

  • 两种减量顺序的24个月累积复发率相似(61% vs 62%)。
  • 先减csDMARD组无DMARD缓解率数值更高但未达统计学显著(21% vs 10%,p=0.07)。
  • DAS、HAQ-DI及影像学进展在两组间均无显著差异。

核心结论

  • 减量顺序不影响复发率、DAS或HAQ-DI,无DMARD缓解在已确诊RA中约15%可达,先减csDMARD者略多。

研究设计与样本

  • 多中心单盲随机对照试验,纳入189例已确诊RA且DAS44≤2.4、肿胀关节数≤1持续≥3个月的患者。
  • 随机分为先渐减csDMARD(约90%为甲氨蝶呤)后减TNF抑制剂组(n=94)或相反顺序组(n=95)。

主要发现

  • 24个月累积复发率:先减csDMARD组61%(95%CI 50%–71%),先减TNF抑制剂组62%(95%CI 52%–72%)。
  • 完成整个减量方案的比例:先减csDMARD组32% vs 先减TNF抑制剂组20%(p=0.12)。
  • 达到无DMARD缓解的比例:先减csDMARD组21% vs 先减TNF抑制剂组10%(p=0.07)。
  • 两组间平均DAS(p=0.45)、HAQ-DI(p=0.17)及影像学进展(p=0.8)均无显著差异。

关键数值与推荐

  • 入组疾病控制标准:DAS44≤2.4且肿胀关节数≤1,持续≥3个月,经csDMARD联合TNF抑制剂达成。

临床怎么用

  • 已确诊RA病情稳定者可考虑逐步减量,两种顺序临床效果相似,可结合费用因素选择先减TNF抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the 2-year clinical effectiveness of two gradual tapering strategies. The first strategy consisted of tapering the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) first (i.e., methotrexate in ~90%), followed by the tumour necrosis factor inhibitor (TNF-inhibitor), the second strategy consisted of tapering the TNF-inhibitor first, followed by the csDMARD. METHODS: This multicentre single-blinded randomised controlled trial included patients with rheumatoid arthritis (RA) with well-controlled disease for ≥3 consecutive months, defined as a Disease Activity Score (DAS) measured in 44 joints ≤2.4 and a swollen joint count ≤1, which was achieved with a csDMARD and a TNF-inhibitor. Eligible patients were randomised into gradual tapering the csDMARD followed by the TNF-inhibitor, or vice versa. The primary outcome was the number of disease flares. Secondary outcomes were DMARD-free remission (DFR), DAS, functional ability (Health Assessment Questionnaire Disability Index (HAQ-DI)) and radiographic progression. RESULTS: 189 patients were randomly assigned to tapering their csDMARD (n=94) or TNF-inhibitor (n=95) first. The cumulative flare rate after 24 months was, respectively, 61% (95% CI 50% to 71%) and 62% (95% CI 52% to 72%). The patients who tapered their csDMARD first were more often able to go through the entire tapering protocol and reached DFR more often than the group that tapered the TNF-inhibitor first (32% vs 20% (p=0.12) and 21% vs 10% (p=0.07), respectively). Mean DAS and HAQ-DI over time, and radiographic progression did not differ between groups (p=0.45, p=0.17, p=0.8, respectively). CONCLUSION: The order of tapering did not affect flare rates, DAS or HAQ-DI. DFR was achievable in 15% of patients with established RA, slightly more frequent in patients that first tapered csDMARDs. Because of similar effects from a clinical viewpoint, financial arguments may influence the decision to taper TNF-inhibitors first.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Mulligen E, Weel AE, Hazes JM, et al. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. Ann Rheum Dis. 2020. PMID: 32482645. doi:10.1136/annrheumdis-2020-217485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。